Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.

about

Ceftobiprole for the treatment of pneumonia: a European perspective Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?Pharmacotherapy for hospital-acquired pneumonia.Emerging drugs for nosocomial pneumonia.

P2860

Q26796463-445B5D42-C287-4E0F-A235-3997CCBA5D89 Q28080607-90AFDF36-C55D-4A58-8FD1-9CD89EAB358B Q38192023-459284B8-13BB-4BDA-AB91-FC9D853A873B Q38878167-03839F71-EF18-43A0-9A5B-6C76CB341F0A

P2860

Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.

Item

http://www.wikidata.org/entity/Q38099393

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Pharmacokinetic and pharmacody ...... f hospital-acquired pneumonia.

@en

type

Item

label

Pharmacokinetic and pharmacody ...... f hospital-acquired pneumonia.

@en

prefLabel

Pharmacokinetic and pharmacody ...... f hospital-acquired pneumonia.

@en

P1476

Pharmacokinetic and pharmacody ...... of hospital-acquired pneumonia

@en

P2093

Ethan Rubinstein

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci

Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004).

Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data.

SHV-type extended-spectrum beta-lactamase production is associated with Reduced cefepime susceptibility in Enterobacter cloacae

Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008).

Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.

Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.

Solving staphylococcal resistance to beta-lactams.

Decline of meticillin-resistant Staphylococcus aureus in Oxfordshire hospitals is strain-specific and preceded infection-control intensification

P304

789-799

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2013.788150

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Philippe Lagacé-Wiens

P577

2013-04-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23590397

http://www.w3.org/2001/XMLSchema#string

P921

Bruschtfiewer

Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.

about

P2860

P2860

Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921